Defunct Company
Total Trials
8
As Lead Sponsor
As Collaborator
0
Total Enrollment
536
NCT03161457
A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 27, 2017
Completion: Apr 16, 2019
NCT03586076
A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects
Start: Jan 26, 2018
Completion: May 21, 2019
NCT03576651
A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers
Start: Mar 24, 2018
Completion: Dec 13, 2019
NCT03670901
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase 3
Start: Nov 13, 2018
Completion: Mar 7, 2019
NCT03670888
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
Start: Nov 16, 2018
Completion: Mar 19, 2019
NCT06308861
Phase 1 to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males
Start: Aug 12, 2020
Completion: Jul 13, 2021
NCT06308874
Phase 1 to Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females
Start: Jan 2, 2023
Completion: Feb 17, 2023
NCT06297434
Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH
Phase: Phase 2
Start: Feb 15, 2023
Completion: Oct 30, 2025